These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34482313)

  • 1. Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management.
    Pi B; Wang J; Tong Y; Yang Q; Lv F; Yu Y
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e858-e867. PubMed ID: 34482313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical features, treatment, and outcome of pembrolizumab induced cholangitis.
    Fang W; Sun W; Fang W; Zhang J; Wang C
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Oct; 397(10):7905-7912. PubMed ID: 38748225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholangitis Induced by Immune Checkpoint Inhibitors: Analysis of Pharmacovigilance Data.
    Meunier L; Hountondji L; Jantzem H; Faillie JL; Maria A; Palassin P;
    Clin Gastroenterol Hepatol; 2024 Jul; 22(7):1542-1545.e4. PubMed ID: 38110061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic guide for immune checkpoint inhibitor-induced liver injury.
    Ito T; Takeuchi Y; Mizuno K; Imai M; Yoshimaru Y; Abe K; Abe M; Matsuura T; Yokode M; Shiokawa M; Kodama Y; Komuta M; Harada K; Tanaka A
    Hepatol Res; 2024 Aug; 54(8):719-726. PubMed ID: 38884591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis.
    Middha P; Thummalapalli R; Betti MJ; Yao L; Quandt Z; Balaratnam K; Bejan CA; Cardenas E; Falcon CJ; Faleck DM; ; Gubens MA; Huntsman S; Johnson DB; Kachuri L; Khan K; Li M; Lovly CM; Murray MH; Patel D; Werking K; Xu Y; Zhan LJ; Balko JM; Liu G; Aldrich MC; Schoenfeld AJ; Ziv E
    medRxiv; 2023 Sep; ():. PubMed ID: 37292751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences between immunotherapy-induced and primary hypophysitis-a multicenter retrospective study.
    Amereller F; Deutschbein T; Joshi M; Schopohl J; Schilbach K; Detomas M; Duffy L; Carroll P; Papa S; Störmann S
    Pituitary; 2022 Feb; 25(1):152-158. PubMed ID: 34518996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort.
    Hountondji L; Ferreira De Matos C; Lebossé F; Quantin X; Lesage C; Palassin P; Rivet V; Faure S; Pageaux GP; Assenat É; Alric L; Zahhaf A; Larrey D; Witkowski Durand Viel P; Riviere B; Janick S; Dalle S; Maria ATJ; Comont T; Meunier L
    JHEP Rep; 2023 Jun; 5(6):100719. PubMed ID: 37138674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study.
    Bae S; Kim YJ; Kim MJ; Kim JH; Yun SC; Jung J; Kim MJ; Chong YP; Kim SH; Choi SH; Kim YS; Lee SO
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34521732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy.
    Kubo T; Hirohashi Y; Tsukahara T; Kanaseki T; Murata K; Morita R; Torigoe T
    Immunol Med; 2022 Jun; 45(2):108-118. PubMed ID: 34542015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Impact of Sarcopenia on Clinical Outcomes in Malignancies Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Li S; Wang T; Tong G; Li X; You D; Cong M
    Front Oncol; 2021; 11():726257. PubMed ID: 34513704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occurrence of Possible Rheumatologic Immune-Related Adverse Events (rh-irAEs) Associated with Immune Checkpoint Inhibitor (ICI) Therapy.
    Anjohrin S; Sheahan A; Suruki R; Stark JL; Sloan VS
    Rheumatol Ther; 2021 Dec; 8(4):1651-1659. PubMed ID: 34491550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review.
    Ueno M; Takabatake H; Hata A; Kayahara T; Morimoto Y; Notohara K; Mizuno M
    Cancer Rep (Hoboken); 2022 Sep; 5(9):e1624. PubMed ID: 35575047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrahepatic Bile Duct Injury as a Hepatic Immune-Related Adverse Event after Immune-Checkpoint Inhibitor Treatment.
    Murayama A; Tajiri K; Nakaya A; Ito H; Hayashi Y; Entani T; Nagata K; Tanaka S; Hamashima T; Yasuda I
    Case Rep Gastroenterol; 2021; 15(2):645-651. PubMed ID: 34616270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholangiopathy in Early Rehabilitation After Intensive Care Treatment of Patients With COVID-19.
    Linneweber L; Mann AB; Denk G; Kraft E; Weber S
    Am J Gastroenterol; 2022 Jan; 117(1):197-198. PubMed ID: 34585676
    [No Abstract]   [Full Text] [Related]  

  • 15. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial.
    Peters S; Pujol JL; Dafni U; Dómine M; Popat S; Reck M; Andrade J; Becker A; Moro-Sibilot D; Curioni-Fontecedro A; Molinier O; Nackaerts K; Insa Mollá A; Gervais R; López Vivanco G; Madelaine J; Mazieres J; Faehling M; Griesinger F; Majem M; González Larriba JL; Provencio Pulla M; Vervita K; Roschitzki-Voser H; Ruepp B; Mitchell P; Stahel RA; Le Pechoux C; De Ruysscher D;
    Ann Oncol; 2022 Jan; 33(1):67-79. PubMed ID: 34562610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients.
    Huang Y; Soon YY; Aminkeng F; Tay SH; Ang Y; Kee ACL; Goh BC; Wong ASC; Soo RA
    Int J Cancer; 2022 Feb; 150(4):636-644. PubMed ID: 34562273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study.
    Lasagna A; Agustoni F; Percivalle E; Borgetto S; Paulet A; Comolli G; Sarasini A; Bergami F; Sammartino JC; Ferrari A; Zavaglio F; Arena F; Lilleri D; Secondino S; Falzoni M; Schiavo R; Klersy C; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
    ESMO Open; 2021 Oct; 6(5):100272. PubMed ID: 34543863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR mutation status in non-small cell lung cancer receiving PD-1/PD-L1 inhibitors and its correlation with PD-L1 expression: a meta-analysis.
    Yang H; Zhu J; Xiao R; Liu Y; Yu F; Cai L; Qiu M; He F
    Cancer Immunol Immunother; 2022 May; 71(5):1001-1016. PubMed ID: 34542660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitor-related hepatotoxicity: A review.
    Remash D; Prince DS; McKenzie C; Strasser SI; Kao S; Liu K
    World J Gastroenterol; 2021 Aug; 27(32):5376-5391. PubMed ID: 34539139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis.
    Dolladille C; Akroun J; Morice PM; Dompmartin A; Ezine E; Sassier M; Da-Silva A; Plane AF; Legallois D; L'Orphelin JM; Alexandre J
    Eur Heart J; 2021 Dec; 42(48):4964-4977. PubMed ID: 34529770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.